KRAS mutations are common in colorectal cancer (30%–50%) and are considered important molecular markers for predicting the efficacy of the anti-EGFR monoclonal antibodies, cetuximab, and panitumumab (23, 24). Here, EGFR is linked to colorectal cancer.